Research Supporting the Use of Ruxolitinib for the Treatment of Myelofibrosis
Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, discusses research supporting the use of ruxolitinib (Jakafi) for the treatment of myelofibrosis.
According to Ali, COMFORT-1 (NCT00952289) and COMFORT-2 (NCT00934544), showed that ruxolitinib showed good responses when compared to best available treatment or other supportive treatments. It was also shown beneficial for the treatment of polycythemia vera.
Ruxolitinib was recently approved for the treatment of graft versus host disease (GvHD) and has shown promise in chronic GvHD. According to Ali, this is due to the unique mechanism of improving inflammation, which is the main driver in patients with myelofibrosis, other myeloproliferative neoplasms, and GvHD.
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
November 12th 2024In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read More
Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML
November 2nd 2024A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.
Read More
